Sarepta Leads Biotech Movers on Voucher Deal News


After a long weekend, thanks to President's Day, Sarepta Therapeutics led the biotech movers Tuesday morning on news that the company sold a priority-review voucher to Gilead for $125 million. Sarepta shares were up 2.55%, hitting $29 per share Tuesday.



from Biotech News